The first stop for professional medicines advice

Medicines planning

61 results

Applied filters

Biosimilar and key generic medicines - delivering better value

11 December 2024An overview of NHS England and NHS SPS roles in implementing biosimilar and key generic medicines and what to expect in 2025/26.

New Product Evaluations

14 November 2024A list of new product evaluations that are freely available to NHS staff.

Using our annual medicines planning publication, Prescribing Outlook

28 October 2024Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.

Implementing ustekinumab biosimilar

4 September 2024This webinar provided information and guidance to support organisations switch to the best value ustekinumab biosimilar

Good governance when implementing ustekinumab biosimilar

2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for ustekinumab biosimilars

2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.

Monitoring and reviewing a PGD in practice

30 July 2024Monitoring and evaluating practice under a PGD and timely review of a PGD are important steps in the development process.

Writing a PGD

30 July 2024Writing a PGD is a multi-step process, requiring input from all members of the PGD development team.

Authorising and preparing to use a PGD

30 July 2024Once a PGD is written, there are steps to be completed before the PGD is used within an organisation.

Planning for a PGD

30 July 2024You’ve decided a PGD is the most appropriate option but there are things to consider before you start writing.
admin